Host factors affecting antiepileptic drug delivery—Pharmacokinetic variability☆
Graphical abstract
Introduction
Antiepileptic drugs (AEDs) are a group of drugs exhibiting extensive pharmacological variability between and within patients. This pharmacokinetic variability is a major determinant of differences in response to treatment. With a prevalence of 0.6–0.8%, epilepsy is one of the most common serious chronic neurological disorder affecting all ages and without ethnic or geographical boundaries. Hence, age, gender, and ethnicity are all host factors that can be of relevance for variability in AED delivery and response. The pharmacokinetics of AEDs can also be affected by specific physiological states in life, such as pregnancy, as well as by pathological conditions including hepatic and renal insufficiency. Additionally, comorbidities are common among people with epilepsy and these conditions often require treatment with drugs that may interact with the co-prescribed AEDs [1]. The increasing use of AEDs in other disorders such as neuropathic pain, migraine, bipolar disorder and anxiety underline the importance of insight into and understanding of the pharmacological variability of AEDs also in new patient populations [2], [3].
Host factors affecting AED delivery may be defined as the pharmacokinetic characteristics that determine the AED delivery to the site of action, the epileptic focus. These are traditionally segregated into absorption, distribution, metabolism and excretion (Fig. 1). In this review, we will discuss each of these pharmacokinetic processes (except delivery to the brain which is covered in a separate chapter) for the presently available AEDs. In doing so, we first provide a general summary of data on individual AEDs followed by a discussion on how the kinetic properties may be affected by individual host factors. The clinical implications will be discussed as well as the possibility to control for pharmacokinetic variability by use of therapeutic drug monitoring (TDM).
The present review is mainly based on recently published articles identified by searches in PubMed and Google Scholar from May 2009 to May 2011, in addition to the authors' files. Selected publications with emphasis on the last five years were included. Relevant peer-reviewed articles for the topic in recognized international journals in English were included, and primary sources were preferred. Abstracts were included where a full publication was not found. Review articles giving a broad and updated overview were also included. The SPC (Summary of Product Characteristics) for each of the drugs were used for specific pharmacokinetic parameters. Unpublished or non-English articles and case reports or clinical studies with a minor methodological and clinical value were excluded. Based upon the searches, a selection of relevant articles was chosen as a basis for the present review. AEDs are defined as the drugs classified as N03A in the Anatomical Therapeutic Classification system (ATC) [4]. The following search terms were used: Category 1, AEDs: Carbamazepine, clobazam, clonazepam, eslicarbazepine acetate, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, pregabalin, primidone, retigabine, rufinamide, stiripentol, tiagabine, topiramate, valproic acid, vigabatrin, zonisamide.
Category 2, Other terms: Absorption, adverse drug effects, clinical study, distribution, drug delivery, drug development, drug surveillance, efficacy, elimination, excretion, formulation, generic substitution, host factors, metabolism, pharmacokinetics, pharmacology, pharmacogenetics, safety, special populations, therapeutic drug monitoring, teratogenicity, and tolerability.
Section snippets
General aspects
The different routes of administration of AEDs are described in detail in a separate chapter of this volume (R. H. Levy). We here focus on oral administration. In general, absorption is extensive and bioavailability high for most AEDs (Table 1). The rate and extent of absorption can, however, vary with the drug formulation. Slow-, extended-, or sustained-release formulations have been developed for some AEDs. The purpose with such formulations is to prolong the absorption time, Tmax, reduce the
General aspects
AEDs are generally widely distributed in the body, and are lipid-soluble so that they may cross the blood–brain barrier to their site of action (Table 2). AEDs are bound to serum proteins to various extents.
Highly protein bound AEDs (≥ 90%)
The serum protein binding of diazepam, phenytoin, stiripentol, tiagabine and valproic acid ranges from 90 to 99% [82], [83], [84], [85], [86], [87] (Table 2). The binding of valproic acid decreases with increasing serum concentrations within the clinically used concentration range [87].
General aspects
Most AEDs undergo extensive metabolism, the main routes being through the cytochrome P450 system (CYP). There are various different CYP isoenzymes, each of which is a specific gene product with characteristic substrate specificity. The P450 enzyme system consists of a super-family of hemoproteins, and the nomenclature is based on similarities in amino acid sequences deduced from genes. Each isoform is identified by three terms representing families and subfamilies: An Arabic numeral designates
General aspects
As described in detail in the previous section, most AEDs are metabolized in the liver, and small fractions of the compound, and their inactive metabolites are excreted through the kidneys. Therefore, for most AEDs, the liver is the major eliminating organ. There are, however some exceptions of drugs that are predominately eliminated through renal excretion: Lacosamide, levetiracetam, gabapentin, pregabalin and vigabatrin. Renal function is determining their rate of elimination (Table 3).
Clinical implications
Pharmacokientic variability is a major determinant of differences in response to AED treatment. This variability largely depends on host factors that may be genetic or of other origin. There is on the one hand an interindividual variability that may be consistent over time. On the other there may be an intraindividual variability with alterations in pharmacokinetics of a specific drug for a particular individual. The latter may develop gradually and to some extent in a predictable manner as
Acknowledgments
The authors have no financial disclosures and no conflict of interest regarding this manuscript.
References (225)
- et al.
Antiepileptic drugs in epilepsy and other disorders: a population-based study of prescriptions
Epilepsy Res.
(2009) - et al.
The pharmacological treatment of epilepsy in adults
Lancet Neurol.
(2011) - et al.
Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy
Clin. Ther.
(2007) - et al.
Comparative daily profiles with different preparations of lamotrigine: A pilot investgation
Epilepsy Behav.
(2008) - et al.
Association between antiepileptic drug switching and epilepsy-related events
Epilepsy Behav.
(2009) - et al.
Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability
Epilepsy Res.
(2000) - et al.
The absorption of gabapentin following high dose escalation
Seizure
(2003) - et al.
Bioequivalence of carbamazepine chewable and conventional tablets: single-dose and steady-state studies
J. Pharmaceut. Sci.
(1985) - et al.
Safety of an IV formulation of carbamazepine
Epilepsy Res.
(2009) - et al.
Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations
J. Pharm. Sci.
(1973)
Eslicarbazepine acetate
Neurotherapeutics
Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokin.
Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group
Lancet
Pharmacokinetics of tiagabine, a g-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses
Epilepsia
ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48(Suppl 5), 2007, pp. 140–149. Erratum in
Epilepsia
Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from International Pharmacogenetic Cohorts
Epilepsia
Status epilepticus in pregnancy: effect of phenytoin malabsorption on seizure control
Neurology
Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy
Drugs
Psychiatric comorbidity in patients with epilepsy: a population-based study
Eur. J. Clin. Pharmacol.
Relations between mechanisms of action and clinical efficacy of antiepileptic drugs in non-epilepsy conditions
CNS Drugs
Extended-release formulations for the treatment of epilepsy
CNS Drugs
Extended-release formulations of antiepileptic drugs: rationale and comparative value
Epilepsy Curr.
Generic products of antiepileptic drugs (AEDs): is it an issue?
Epilepsia
Debate: Substitution of generic drugs in epilepsy: is there cause for concern?
Epilepsia
Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability
Epilepsia
Compulsory generic switching of antiepileptic drugs: high switch-back rates to branded compounds compared with other drug classes
Epilepsia
The risks and costs of multiple-generic substitution of topiramate
Neurology
Refilling and switching of antiepileptic drugs and seizure-related events
Clin. Pharmacol. Ther.
Seizure outcomes following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis
Drugs
Pharmacokinetics and metabolism of gabapentin in rat, dog and man
Arzneim. Forsch. Drug Res.
A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma
Pharm. Res.
The Epilepsy Prescriber's Guide to Antiepileptic Drugs
A comparative bioavailability study of carbamazepine tablets and a chewable tablet formulation
Ther. Drug Monit.
A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients
Br. J. Clin. Pharmacol.
Replacing carbamazepine slow-release tablets with carbamazepine suppositories: a pharmacokinetic and clinical study in children with epilepsy
J. Child Neurol.
Pharmacokinetics of single and multiple doses of clobazam in humans
Br. J. Clin. Pharmacol.
Clobazam kinetics: intrasubject variability and effect of food on absorption
J. Clin. Pharmacol.
Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and repeated administration
Eur. J. Clin. Pharmacol.
Serum clonazepam concentrations in children with absence seizures
Neurology
The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma
J. Clin. Psychopharmacol.
A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of the new diazepam rectal gel with intravenous diazepam
Epilepsia
Absorption and elimination of ethosuximide in children
J. Clin. Pharmacol.
Pharmacokinetics of drugs used for petit mal ‘absence’ epilepsy
Clin. Exp. Neurol.
Comparative bioavailability of felbamate in healthy men
Epilepsia
Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures
Expert Rev. Neurother.
The influence of dosage, age, and comedication on steady state serum lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response
Ther. Drug Monit.
Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service
Br. J. Clin. Pharmacol.
Cited by (88)
Pharmaceutical dry powders of small molecules prepared by thin-film freezing and their applications – A focus on the physical and aerosol properties of the powders
2022, International Journal of PharmaceuticsExtensive pharmacokinetic variability of Levetiracetam. ¿Are doctors aware?
2022, Epilepsy Research
- ☆
This review is part of the Advanced Drug Delivery Reviews theme issue on "Antiepileptic Drug Delivery".